tbuckley/cabot-search huggingface dataset:
A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy (EPP) and postoperative hemithoracic radiation (H-RT) for malignant pleural mesothelioma (MPM): First all-Japan trial.
Authors: Fumihiro Tanaka, Seiki Hasegawa, Morihito Okada, Takeharu Yamanaka, Toshinori Soejima, Norihiko Kamikonya, Kazuya Fukuoka, Kohei Yokoi, Takashi Nakano
Journal: Journal of Clinical Oncology (2013)

7583 Background: The first all Japan multi-institutional trial was conducted to evaluate the feasibility of tri-modality therapy for MPM with support by the Special Coordination Funds for Promoting Science and Technology from the Japanese Ministry of Education, Culture, Sports, Science and Technology, and the first analyses data including macroscopic complete resection (MCR) rate by EPP as well as treatment-related mortality were presented at the ESMO meeting 2011 after completion of planned patient enrollment, and all survival data collection has been completed in January 2013. Methods: Major eligibility criteria: a histologically confirmed diagnosis of MPM, including all subtypes clinical T0–3, N0–2, M0 disease considered to be completely resectable; no prior treatment for the disease; age between 20 and 75 years; ECOG performance status of 0 or 1; a predicted postoperative forced expiratory volume in 1 s of &gt;1000 ml; and written informed consent. Treatment methods: Induction chemotherapy of pemetrexed 500 mg/m 2 plus cisplatin 60 mg/m 2 for 3 cycles, followed by EPP and postoperative H-RT (54 Gy). Primary endpoints: MCR rate by EPP and treatment-related mortality for tri-modality therapy. Results: A total of 17 institutions in Japan with certified specialists in oncology, surgery and radiation therapy participated in this trial. The study was initiated in May 2008 and patient enrollment was completed in November 2010 with 42 eligible patients. Median age 64.5 (range 43–74), M: F = 39:3, Clinical stage I:II:III = 14:13:15, Histological type epithelial: sarcomatous; biphasic; others = 28: 1: 9: 4. The trial met the primary endpoints with MCR rate of 71% and treatment-related mortality of 9.5%. All survival data to calculate disease-free survival and overall survival at 2 years after EPP have been collected, and results will be presented at the meeting. Conclusions: Results of the present trial will be the foundation of treatment strategy for resectable MPM. Clinical trial information: 000001154.
Delivering Good News
Authors: Shan Ali
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Association Between Maternal Fluoride Exposure and Child IQ
Authors: Sarah Farrow, Ari R. Joffe
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Physiological consequences of transient hyperleptinemia during discrete developmental periods on body weight in mice
Authors: Alicja A. Skowronski, Charles A. LeDuc, Kylie S. Foo, Yossef Goffer, Lisa C. Burnett, Dieter Egli, Rudolph L. Leibel
Journal: Science Translational Medicine (2020)

Hyperleptinemia without weight gain during the immediate postnatal period exacerbates later diet-induced obesity in male and female mice.
Unusual case of preoperative hypoxaemia
Authors: Padraic C Ridge, Sarah Cullivan, Christina D Campbell, Anthony O"Regan, Robert M Rutherford
Journal: Thorax (2020)

The necessity for palliative surgery in transposition of the great vessels is indicated and the basic haemodynamics of the condition are outlined. The clinical picture of infants with transposition is divided into three types, and a method of surgical treatment is suggested for the two most common types. Our technique of investigation and treatment is described and the reasons for our choice of therapy are discussed. The results of cases operated upon are presented.
It’s about time: clocks in the developing lung
Authors: Colleen M. Bartman, Aleksey Matveyenko, Y.S. Prakash
Journal: Journal of Clinical Investigation (2020)

The discovery of peripheral intracellular clocks revealed circadian oscillations of clock genes and their targets in all cell types, including those in the lung, sparking exploration of clocks in lung disease pathophysiology. While the focus has been on the role of these clocks in adult airway diseases, clock biology is also likely to be important in perinatal lung development, where it has received far less attention. Historically, fetal circadian rhythms have been considered irrelevant owing to lack of external light exposure, but more recent insights into peripheral clock biology raise questions of clock emergence, its concordance with tissue-specific structure/function, the interdependence of clock synchrony and functionality in perinatal lung development, and the possibility of lung clocks in priming the fetus for postnatal life. Understanding the perinatal molecular clock may unravel mechanistic targets for chronic airway disease across the lifespan. With current research providing more questions than answers, it is about time to investigate clocks in the developing lung.
First results of the prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Authors: Pat W. Whitworth, Mark Gittleman, Stephanie Akbari, Lisette Stork, Femke De Snoo, Jessica Gibson, Peter D. Beitsch
Journal: Journal of Clinical Oncology (2013)

e22117 Background: Classification into molecular subtypes may be important for the selection of therapy for patients with early breast cancer. Previous analyses had shown that breast cancer subtypes have distinct clinical outcome (Sorlie, PNAS 2001; Esserman, BCRT 2011). The aim of the prospective NBRST study is to measure chemosensitivity as defined by pathological Complete Response (pCR), or endocrine sensitivity as defined by partial response (PR) and metastasis-free survival in molecular subgroups. Methods: The study includes women aged 18–90 with histologically proven breast cancer, who are scheduled to start neo-adjuvant chemotherapy (CT) or neo-adjuvant endocrine therapy (ET), and who provide written informed consent. Additional inclusion criteria include no excision biopsy or axillary dissection, no confirmed distant metastatic disease, and no prior therapy for breast cancer. Treatment is at the discretion of the physician adhering to NCCN approved regimens. 500 Patients will be enrolled. Results: 128 Patients (median age 52, range 22-79), T1-4 N0-3, had definitive surgery and the overall pCR rate was 22%.14 (11%) patients are classified as Luminal A-type (BluePrint Luminal/MammaPrint Low Risk) of whom 11 received neo-adjuvant CT; none of these patients had a pCR. While 3 patients received neo-adjuvant ET and all 3 had a PR. 47 (37%) Patients are classified as Luminal B-type (BluePrint Luminal/MammaPrint High Risk). All but 1 patient received neo-adjuvant CT and 4 (9%) had a pCR. 20 (16%) Patients are classified as BluePrint HER2-type and received neo-adjuvant CT plus Trastuzumab; 8 (40%) had a pCR. 47 (37%) Patients are classified as BluePrint Basal-type and received neo-adjuvant CT; 15 (32%) had a pCR. Of the patients with IHC/FISH HER2+ cancer 13/39 (33%) had a pCR and 6/21 (29%) of the patients with IHC/FISH triple negative breast cancer. Conclusions: We observed differences in pCR to neo-adjuvant treatment in groups stratified by BluePrint and MammaPrint. Patients with Luminal A-type breast cancer have a high response to neo-adjuvant endocrine therapy (100% PR) and no pCR to neo-adjuvant CT. While patients with BluePrint HER2-type and Basal-type breast cancer have a high pCR rate to neo-adjuvant CT. Clinical trial information: NCT01479101.
Re-recognition of pseudogenes: From molecular to clinical applications
Authors: Xu Chen, Lin Wan, Wei Wang, Wen-Jin Xi, An-Gang Yang, Tao Wang
Journal: Theranostics (2020)

Pseudogenes were initially regarded as "nonfunctional" genomic elements that did not have protein-coding abilities due to several endogenous inactivating mutations.Although pseudogenes are widely expressed in prokaryotes and eukaryotes, for decades, they have been largely ignored and classified as gene "junk" or "relics".With the widespread availability of high-throughput sequencing analysis, especially omics technologies, knowledge concerning pseudogenes has substantially increased.Pseudogenes are evolutionarily conserved and derive primarily from a mutation or retrotransposon, conferring the pseudogene with a "gene repository" role to store and expand genetic information.In contrast to previous notions, pseudogenes have a variety of functions at the DNA, RNA and protein levels for broadly participating in gene regulation to influence the development and progression of certain diseases, especially cancer.Indeed, some pseudogenes have been proven to encode proteins, strongly contradicting their "trash" identification, and have been confirmed to have tissue-specific and disease subtype-specific expression, indicating their own value in disease diagnosis.Moreover, pseudogenes have been correlated with the life expectancy of patients and exhibit great potential for future use in disease treatment, suggesting that they are promising biomarkers and therapeutic targets for clinical applications.In this review, we summarize the natural properties, functions, disease involvement and clinical value of pseudogenes.Although our knowledge of pseudogenes remains nascent, this field deserves more attention and deeper exploration.
Genomic rearrangements in lung adenocarcinoma: Lineage relationships between the in situ and invasive components.
Authors: Stephen J Murphy, Dennis A. Wigle, Faye R Harris, Joema Felipe Lima, Sarah H Johnson, Bruce W Eckloff, Charlie T Seto, Michael Asiedu, Tobias Peikert, Ping Yang, Marie-Christine Aubry, George Vasmatzis
Journal: Journal of Clinical Oncology (2013)

7568 Background: The molecular events in the initiation and progression of invasive lung adenocarcinoma remain poorly characterized. These tumors are thought to develop through an adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), invasive adenocarcinoma (AD) sequence. The goal of our study was to assess lineage relationships between in situ and invasive components within adenocarcinomas with prominent lepidic growth patterns. Methods: Frozen tissue from fourteen lung adenocarcinomas with mixtures of AD together with an adjacent in situ component (AIS), varying in ratio between 40 to 80%, were selected from our Lung Specimen Registry. Laser capture microdissection (LCM) of each component was performed separately for each tumor. Genomic DNA was isolated using a direct in situ whole genome amplification (WGA) methodology, and Next Generation Sequencing performed using an Illumina Mate Pair (MP) library protocol. MP sequence reads were mapped to the human genome and primers spanning the fusion junctions were used in validation PCRs. Results: Genomic break points identical and unique to a specific patient were identified between the AIS and AD components in 13 (of 14) cases. The total number of events per case ranged from 4-215, and the number of identical events shared between the AIS and AD components ranged from 30 to 90%. Recurrent genomic breakpoints between cases were also observed, with the 2 most common involving 8q24.3 in 5 cases and FAM19A2 on chromosome 12 in 4 cases. PCR validation of selected genomic alterations confirmed the genomic break points identified from sequencing in both the AIS and AD in all cases. Interestingly, we also observed a limited number of genomic alterations present in a zonal distribution of surrounding normal lung around the tumor mass. Conclusions: Our study demonstrates unique chromosomal alterations present in both the AIS and AD components of individual lung tumors with features of lepidic growth. These data provide evidence for lineage relationship and clonal relatedness between the two components, and provide genomic evidence for a model of stepwise progression from AIS to invasive AD in this subset of lung adenocarcinomas.
Environmental shedding of toxigenic Clostridioides difficile by asymptomatic carriers: A prospective observational study
Authors: M. Gilboa, E. Houri-Levi, C. Cohen, I. Tal, C. Rubin, O. Feld-Simon, A. Brom, Y. Eden-Friedman, S. Segal, G. Rahav, G. Regev-Yochay, Howard Amital, Sharon Beni, Ilan Ben-Zvi, Natasha Blausov, Adi Brom, Carmit Cohen, Olga Feld-Simon, Ronen Fluss, Mayan Gilboa, Yehudit Eden-Friedman, Shiraz Halevy, Esther Houri-Levi, Amit Hupert, Amnah Jbarien, Naty Keller, Avshalom Leibowitz, Haim Mayan, Leonid Maizels, Eyal Meltzer, Nani Pinas-Zade, Galia Rahav, Shir Raibman-Spector, Gili Regev-Yochay (PI), Marina Romiantsev, Dalit Shachar, Kassem Sharif, Gadi Segal, Shoshi Segal, Amitai Segev, Gill Smollan, Shmuel Stienlauf, Ilana Tal, Hagit Yonath, Tal Zilberman-Daniels, Eyal Zimlichman
Journal: Clinical Microbiology and Infection (2020)
Case-control study of prophylactic cranial irradiation in nonmetastatic non-small cell lung cancer.
Authors: Simon Cheng, Michael Nino Corradetti, David Paul Horowitz, Eric Xanthopoulos, Amanda Lusa, K. S. Clifford Chao, Ramesh Rengan
Journal: Journal of Clinical Oncology (2012)

7050 Background: Prophylactic cranial irradiation (PCI) reduces the incidence of brain metastases in NSCLC patients after primary therapy, but its impact on survival is uncertain. We report on the largest study of survival in patients treated with and without PCI for non-small cell lung cancer (NSCLC). Methods: We reviewed 17 Surveillance, Epidemiology and End Results (SEER) registries for a retrospective study on patients who had PCI as part of their primary treatment for NSCLC from 1988 - 97. Cases were limited to those with non-metastatic (Stage I-III) NSCLC. To balance the cohorts, we matched each PCI patient with four non-PCI patients on stage, histology, race and sex. Associations between treatment type, clinical factors, and demographics were assessed using the Chi-squared test. Survival time was calculated as the number of months from diagnosis to the date of death. Survival was censored as of the last month when patients were known to be alive. Overall (OS) and cancer cause-specific survival (CSS) were investigated using the Kaplan-Meier, competing risks, Cox proportional hazards, and log-rank tests. Results: We found 472 PCI matched to 1,888 non-PCI patients. Characteristics were balanced across groups: race (p = 1.00), sex (p = 0.95), histology (p = 1.00), stage (p = 1.00), and surgery (p = 0.81). PCI group was younger, median age 64 vs 68 (p &lt; 0.01). PCI vs no PCI median OS was 8 vs 10 months (p &lt; 0.01). OS was 14% vs 28% at 2 years and 5% vs 12% at 5 years, PCI vs no PCI respectively (p &lt; 0.01). Stage III OS was also different; 10% vs 21% at 2 years, PCI vs no PCI respectively (p &lt; 0.01). Median CSS was the same at 9 months in both groups. Median follow-up was 14 years. Conclusions: PCI was not associated with improved OS or CSS in these NSCLC patients, and PCI may have a detrimental effect on OS. In limited-stage small cell lung cancer, a retrospective SEER analysis during the 1988 – 97 period showed a survival benefit in treated patients with PCI, which has been confirmed with prospective studies. To date, 4 prospective trials examining PCI for NSCLC have shown a reduced incidence of brain metastases, but the effect on survival is unclear. Further investigation is needed to determine whether PCI for NSCLC increases the risk of other causes of death.
A comparison of five ways to measure atopic dermatitis severity in adults
Authors: J.I. Silverberg, D.J. Margolis, M. Boguniewicz, L. Fonacier, M.H. Grayson, P.Y. Ong, Z.C. Fuxench, E.L. Simpson
Journal: British Journal of Dermatology (2020)

Atopic dermatitis (AD), also known as atopic eczema, is a common skin disease, especially in childhood.
Abstract 11853: Clinical Manifestation of Early Phase Left Ventricular Rupture Complicating Acute Myocardial Infarction in the Primary PCI Era
Authors: Masatsugu Nozoe, Tomohiro Sakamoto, Eiji Taguchi, Koichi Nakao
Journal: Circulation (2011)

Background: Before reperfusion therapy was introduced, the incidence of ventricular septal and left ventricular free wall rupture complicating acute myocardial infarction (AMI) was 1% to 3%. In cas...
Clinicopathological implications of EpCAM expression in non-small cell lung cancer
Authors: Myung-ju Ahn
Journal: Cancer Research (2008)

2162  Epithelial cell adhesion molecule (EpCAM) is a type I transmembrane glycoprotein involved in intercellular adhesion and overexpressed in various human epithelial carcinomas. This study was conducted to investigate the frequency of EpCAM expression in non-small cell cancer (NSCLC) cells and human tissues and also to evaluate the clinicopathological significance of EpCAM expression in NSCLC.  We investigated EpCAM expression in several human NSCLC cells (A549, PC14PE6, H661 and H520) and found robust expression in a subset of these cells. EpCAM protein expression in 95 NSCLC tissues was evaluated by immunohistochemistry, and correlation with clinicopathlogic factors and clinical outcome was analyzed.  EpCAM overexpression was detected in 40 of 95 surgically resected NSCLC tissues (42.1%). The expression of EpCAM was not associated with tumor size, regional lymph node metastasis, or tumor stage. The overall survival did not show any significant difference in patients with EpCAM-negative tumors and EpCAM-positive tumors (80.1 vs 76 months: p=0.96).  Although the prognostic value of EpCAM expression in NSCLC still remains controversial, a high frequency of EpCAM overexpression in NSCLC indicate that it may play a role in the carcinogenesis and/or tumor progression of this disease. Further molecular studies are ongoing to evaluate the clinical implications of EpCAM in NSCLC patients.
FVIII Protein Is Not Detectable in Human PBMCs or Livers from Dogs with an Intron-22 Inversion Mutation: Implications for FVIII Immunogenicity and Tolerance
Authors: Devi Gunasekera, Pooja Vir, Ahmad Faisal Karim, Margaret V. Ragni, Elizabeth P. Merricks, Timothy C. Nichols, Kathleen P. Pratt
Journal: Blood (2019)
Brightness analysis in contrast-enhanced ultrasound using sonazoid for breast cancer.
Authors: Norio Masumoto, Takayuki Kadoya, Etsushi Akimoto, Keiko Kajitani, Akiko Emi, Hideo Shigematsu, Rumi Haruta, Tsuyoshi Kataoka, Morihito Okada
Journal: Journal of Clinical Oncology (2013)

e22113 Background: We evaluated the contrast effects of Sonazoid in tumor tissue according to brightness intensity, in cases pathologically diagnosed with breast cancer. Methods: Six cases of ductal carcinoma in situ (DCIS) and seven cases of invasive ductal carcinoma (IDC) diagnosed with needle or Mammotome biopsy between September and December 2012 were examined. The mean ages of the DCIS and IDC cases were 51.7 ± 11.8 years and 62.5 ± 15.7 years respectively. In the IDC cases, tumor diameter was 6-10 mm in three cases, 11-20 mm in three cases and over 50 mm in one case. Two IDC cases were of the luminal A subtype, three cases were luminal B and two cases were triple negative. The ultrasound equipment used was HI VISION ASCENDUS (Hitachi Medical Corporation). The contrast agent, Sonazoid, was administered intravenously at 0.01ml/kg, and for approximately 50 seconds, the tumor sections were fixated and underwent imaging. Sonazoid brightness in the tumor was digitized and a time intensity curve was created based on brightness intensity and time changes. Early and peak contrast brightness was then compared in order to objectively examine changes in contrast effects. Results: Peak brightness was 1.6 ± 0.3 times and 4.8 ± 3.2 times the early brightness in DCIS and IDC cases respectively, indicating a more significant increase in IDC cases (P &lt; 0.05). Comparison according to subtype in IDC cases also revealed a strong increasing trend in triple negative cases, with results showing that peak brightness compared to early brightness was 9.1 times greater in triple negative cases, 2.7 times greater in luminal A cases and 3.3 times greater in luminal B cases. Classification of IDC cases according to nuclear grade (NG) found that peak brightness was 6.2 times greater than early brightness in NG3 cases, 5.7 times greater in NG2 cases and 1.7 times greater in NG1 cases. Conclusions: Brightness intensity, when digitized and analyzed, could be applied to the differential diagnosis of DCIS and IDC. Brightness intensity may also exhibit correlations with subtypes and NG, suggesting that it could be applied to malignancy grading, as well as the prediction of effects of drug therapy and effect measurement.